Technology area: Biotechnology & Pharmaceuticals
26 pending office actions • 19 art units • 25 examiners • 0 of 26 (0%) have an AI response strategy ready • 48 patents granted in the last 365 days
GENZYME Corporation has 29 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 28 distinct examiners across 22 distinct art units, indicating broad examiner coverage with repeated activity in some units.
BRETZ, COREY LANE is the busiest listed examiner, with 2 pending matters. The limited concentration means the portfolio requires coordination across many examination relationships. Art-unit grouping can provide structure, but each response should remain tied to its assigned examiner and application.
Based on the USPTO statutory response window for each pending office action. 10 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 10 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (19%) |
| §103 only | 9 (35%) |
| §102 only | 1 (4%) |
| §112 only | 5 (19%) |
| Double-patenting + other | 2 (8%) |
| Multi-statute (no §101) | 3 (12%) |
| No statute on record | 1 (4%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRETZ, COREY LANE | 2 | 0.0% | +0.0% |
| PATEL, JAY M | 1 | 65.0% | +39.6% |
| TIEDEMAN, JASON S | 1 | 28.5% | +34.9% |
| GILL, RACHEL B | 1 | 65.4% | +28.8% |
| VAN BUREN, LAUREN K | 1 | 40.0% | +58.4% |
| MIDDLETON, DANAYA L | 1 | 49.5% | +48.8% |
| JACKSON III, WALTER | 1 | 50.0% | +0.0% |
| HEASLEY, MEGHAN CHRISTINE | 1 | 74.5% | +36.3% |
| HANEY, AMANDA MARIE | 1 | 36.5% | +45.0% |
| LI, BAO Q | 1 | 75.5% | +26.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 14004377 | PEGYLATED APELIN AND USES THEREOF | KOMATSU, LI N | 44d overdue |
| 18296283 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | BRETZ, COREY LANE | 56d |
| 19481938 | PREDICTING MOTOR FUNCTION SCORES IN POMPE DISEASE TREATMENT | PATEL, JAY M | — |
| 19128502 | Machine Learning Systems and Methods to Identify Locations of Potential Patients and/or Healthcare Providers | TIEDEMAN, JASON S | — |
| 18648199 | METHODS OF IMPROVING RAAV PRODUCTION | VAN BUREN, LAUREN K | — |
| 18626784 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | BRETZ, COREY LANE | — |
| 18560569 | NOVEL PREDICTIVE BIOMARKERS FOR SECONDARY AUTOIMMUNITY AFTER LYMPHOCYTE DEPLETING THERAPY | HANEY, AMANDA MARIE | — |
| 18331748 | Treatment of Hemophilia with Fitusiran | INAM, SAHAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18644528 | HUMANIZED ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF | MIDDLETON, DANAYA L | 13d |
| 19481938 | PREDICTING MOTOR FUNCTION SCORES IN POMPE DISEASE TREATMENT | PATEL, JAY M | — |
| 19128502 | Machine Learning Systems and Methods to Identify Locations of Potential Patients and/or Healthcare Providers | TIEDEMAN, JASON S | — |
| 18797302 | ANALYTICAL ULTRACENTRIFUGATION FOR CHARACTERIZATION OF RECOMBINANT VIRAL PARTICLES | GILL, RACHEL B | — |
| 18648199 | METHODS OF IMPROVING RAAV PRODUCTION | VAN BUREN, LAUREN K | — |
| 18593643 | INDOLE COMPOUNDS AND METHODS OF USE | HEASLEY, MEGHAN CHRISTINE | — |
| 18560569 | NOVEL PREDICTIVE BIOMARKERS FOR SECONDARY AUTOIMMUNITY AFTER LYMPHOCYTE DEPLETING THERAPY | HANEY, AMANDA MARIE | — |
| 18282739 | SIZE EXCLUSION CHROMATOGRAPHY ANALYSIS OF EMPTY AND FULL AAV CAPSIDS | LI, BAO Q | — |
| Art Unit | Apps |
|---|---|
| 1635 | 3 |
| 1671 | 2 |
| 1638 | 2 |
| 1622 | 2 |
| 1628 | 2 |
| 1675 | 2 |
| 3681 | 1 |
| 3683 | 1 |
| 1674 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19481938 | PREDICTING MOTOR FUNCTION SCORES IN POMPE DISEASE TREATMENT | PATEL, JAY M | 3681 | §101§103 | Non-Final OA | — | Pending | Nov 06, 2025 |
| 19128502 | Machine Learning Systems and Methods to Identify Locations of Potential Patients and/or Healthcare Providers | TIEDEMAN, JASON S | 3683 | §101§103§112 | Non-Final OA | — | Pending | May 08, 2025 |
| 18797302 | ANALYTICAL ULTRACENTRIFUGATION FOR CHARACTERIZATION OF RECOMBINANT VIRAL PARTICLES | GILL, RACHEL B | 1671 | §103§112DP | Non-Final OA | — | Pending | Aug 07, 2024 |
| 18648199 | METHODS OF IMPROVING RAAV PRODUCTION | VAN BUREN, LAUREN K | 1638 | §102§103 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18644528 | HUMANIZED ANTI-COMPLEMENT FACTOR BB ANTIBODIES AND USES THEREOF | MIDDLETON, DANAYA L | 1674 | §112 | Final Rejection | 13d | Pending | Apr 24, 2024 |
| 18626784 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | BRETZ, COREY LANE | 1635 | §101§102§103§112DP | Non-Final OA | — | Pending | Apr 04, 2024 |
| 18607056 | Treatment of Dry Age-Related Macular Degeneration | JACKSON III, WALTER | 1638 | §103Other | Non-Final OA | — | Pending | Mar 15, 2024 |
| 18593643 | INDOLE COMPOUNDS AND METHODS OF USE | HEASLEY, MEGHAN CHRISTINE | 1626 | §112 | Non-Final OA | — | Pending | Mar 01, 2024 |
| 18560569 | NOVEL PREDICTIVE BIOMARKERS FOR SECONDARY AUTOIMMUNITY AFTER LYMPHOCYTE DEPLETING THERAPY | HANEY, AMANDA MARIE | 1682 | §101§102§112 | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18282739 | SIZE EXCLUSION CHROMATOGRAPHY ANALYSIS OF EMPTY AND FULL AAV CAPSIDS | LI, BAO Q | 1671 | §112 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18463047 | HYPERGLYCOSYLATED BINDING POLYPEPTIDES | HUYNH, PHUONG N | 1641 | Other | Final Rejection | — | Pending | Sep 07, 2023 |
| 18331748 | Treatment of Hemophilia with Fitusiran | INAM, SAHAR | 1622 | §102§103 | Non-Final OA | — | Pending | Jun 08, 2023 |
| 18256199 | TREATMENT OF HEMOPHILIA WITH FITUSIRAN | FAN, LYNN Y | 1759 | §103 | Non-Final OA | — | Pending | Jun 06, 2023 |
| 18141128 | INDUCTION OF IMMUNE TOLERANCE BY USING METHOTREXATE | LEE, CHIHYI NMN | 1628 | §112DP | Final Rejection | — | Pending | Apr 28, 2023 |
| 18296283 | TARGETED GENE THERAPY FOR DM-1 MYOTONIC DYSTROPHY | BRETZ, COREY LANE | 1635 | §101§103DP | Final Rejection | 56d | Pending | Apr 05, 2023 |
| 18025847 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | VAJDA, KRISTIN ANN | 1622 | §102 | Final Rejection | 36d | Pending | Mar 10, 2023 |
| 18007433 | METHODS FOR REDUCING GLYCOSPHINGOLIPID CONCENTRATION IN BRAIN TISSUE AND METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES INVOLVING THE SAME | SZNAIDMAN, MARCOS L | 1628 | §103 | Final Rejection | 37d overdue | Pending | Jan 30, 2023 |
| 18155655 | SERPINC1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | SHIN, DANA H | 1635 | §112Other | Final Rejection | — | Pending | Jan 17, 2023 |
| 17918973 | ECLITASERTIB FOR USE IN TREATING CONDITIONS INVOLVING SYSTEMIC HYPERINFLAMMATORY RESPONSE | HUTTER, GILLIAN A | 1625 | §103 | Non-Final OA | — | Pending | Oct 14, 2022 |
| 18045995 | FGFR3 ANTIBODIES AND METHODS OF USE | ALLEN, MARIANNE P | 1647 | §112 | Final Rejection | 26d | Pending | Oct 12, 2022 |
| 17843812 | ANTI-TGF-BETA ANTIBODY FORMULATIONS AND THEIR USE | BERHANE, SELAM | 1675 | §103 | Final Rejection | 27d | Pending | Jun 17, 2022 |
| 17721003 | METHODS OF PERFUSION CULTURING A MAMMALIAN CELL | LEVIN, JOEL D | 1633 | §103 | Non-Final OA | 74d overdue | Pending | Apr 14, 2022 |
| 17375785 | METHODS AND COMPOSITIONS FOR TREATING A SERPINC1-ASSOCIATED DISORDER | POLIAKOVA-GEORGAN, EKATERINA | 1637 | §103Other | Final Rejection | 54d | Pending | Jul 14, 2021 |
| 17283433 | GENERATION OF IMPROVED HUMAN PAH FOR TREATMENT OF SEVERE PKU BY LIVER-DIRECTED GENE REPLACEMENT THERAPY | NICOL, ALEXANDER W | 1634 | §103 | Final Rejection | — | Pending | Apr 07, 2021 |
| 16088031 | BIOMARKERS OF PROTEOPATHIES AND USES THEREOF | FONTAINHAS, AURORA M | 1675 | §103 | Final Rejection | 35d | Pending | Sep 24, 2018 |
| 14004377 | PEGYLATED APELIN AND USES THEREOF | KOMATSU, LI N | 1658 | §103§112 | Non-Final OA | 44d overdue | Pending | Feb 10, 2014 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGENZYME Corporation has 26 pending office actions as of October 2026, spread across 19 art units and 25 examiners.
Corey Lane Bretz has the most, with 2 of GENZYME Corporation's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
